冠心病室性心律失常患者的药物治疗分析

Analysis of Drug Therapy in Patients With Ventricular Arrhythmia of Coronary Heart Disease

目的探讨在对冠心病并室性心律失常患者治疗中通过联用胺碘酮及美托洛尔的治疗价值。方法抽取院内自2017年2月—2018年2月住院的86例冠心病并室性心律失常患者作为对象。以数字法随机分组。对照组单独以胺碘酮治疗,观察组则联合胺碘酮及美托洛尔予以治疗,比较两组患者的治疗总有效率及不良反应情况。结果观察组患者的治疗总有效率为97.67%,对照组患者的治疗总有效率为88.37%,且两组对比,差异具有统计学意义(P<0.05);观察组患者的药物不良反应率为6.98%,对照组为9.30%,两组比较,差异无统计学意义(P>0.05)。结论针对冠心病并室性心律失常者通过联用胺碘酮及美托洛尔可取得满意疗效,且安全性良好。

Objective To investigate the therapeutic value of amiodarone and metoprolol in the treatment of patients with coronary heart disease and ventricular arrhythmia. Methods 86 patients with coronary heart disease and ventricular arrhythmia hospitalized from February 2017 to February 2018 were selected as subjects. Random grouping by digital method. The control group was treated with amiodarone alone. The observation group was treated with amiodarone and metoprolol. The total effective rate and adverse reactions of the two groups were compared. Results The total effective rate was 97.67% in the observation group and 88.37% in the control group, and the difference between the two groups was statistically significant (P < 0.05). The rate of adverse drug reactions was 6.98% in the observation group and 9.30% in the control group. There was no significant difference between the two groups (P > 0.05). Conclusion For patients with coronary heart disease and ventricular arrhythmia, a combination of amiodarone and metoprolol can achieve satisfactory results with good safety.